32
total announcements
SYNCOMF.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹2,013 Cr
P/E (TTM)
22.8
EPS (TTM)
₹0.94
52W Low
₹10.21
52W High
₹27.49
Dividend Yield
0.46%
Beta
0.83
Price / Book
4.8
Debt / Equity
0.4
Revenue (TTM)
₹498 Cr
Gross Margin
43.56%
Operating Margin
19.65%
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on stock exchanges.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about the approval and payment of a final dividend of Rs. 0.10 (10%) per Equity Share for the financial year 2025-26, as approved by the 38th Annual General Meeting held on 30th September, 2026.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about change in Management, with the appointment of Shri Rahul Vijay Bankda as Managing Director and Smt. Rinki Ankit Bankda as Whole Time Director, and the re-appointment of Smt. Ruchi Jindal as Woman Independent Director.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about General Updates, including the outcome of the 38th Annual General Meeting held on September 30, 2026, where members approved various resolutions, including the adoption of audited financial statements, declaration of a 10% dividend, and appointment of new directors.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 30, 2026, and informed the Exchange regarding voting results.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has held its 38th Annual General Meeting through video conferencing, with 73 members in attendance, and has enabled members to participate and vote through remote e-voting and e-voting at the meeting.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about General Updates, specifically that the Promoters/Promoter Group have voluntarily waived/foregone their entitlement to receive the final dividend proposed by the Company for the financial year ended 31st March, 2026.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The window for trading in the shares of the Company shall remain closed from 1st October, 2026 till the completion of 48 hours after the declaration of the Un-Audited Standalone & Consolidated Financial Results for the quarter and half year ended 30th September, 2026.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has announced the record date for determining the entitlement of members for payment of dividend at the rate of 10% for the financial year 2025-26, subject to approval by the members at their ensuing 38th Annual General Meeting.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about the submission of a copy of newspaper clippings of the Notice of 38th Annual General Meeting (AGM), Remote E-Voting, Record Date and other details.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about General Updates, specifically regarding the dispatch of letters to shareholders who have not registered their email addresses, and the notice of the 38th Annual General Meeting and Annual Report for the Financial Year 2025-26.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI (LODR) Regulations, 2015.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about Shareholders meeting for the 38th Annual General Meeting scheduled to be held on September 30, 2026.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication regarding Notice of 38th Annual General Meeting (AGM), Remote E-Voting, Book Closure and other details.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited reported strong Q1 FY 2026-27 results with 8% growth in consolidated income and 59% increase in profit before tax, driven by ethical prescription-led model and quality manufacturing.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed regarding the resignation of its Managing Director, Mr. Vijay Shankarlal Bankda, with effect from 11th August, 2026, due to leadership transition and effective succession planning.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed about the resignation of Mr. Kedarmal Shankarlal Bankda as Whole-Time Director, effective from 11th August, 2026, citing reasons of timely succession planning and health well-being.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about the submission of a copy of a newspaper publication related to the extract of un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The company has also announced the 42nd Annual General Meeting (AGM) of Vistar Amar Limited, a related party, which will be held on September 22, 2026.
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has informed the Exchange about the resignation of a Director/KMP/SMP.